Oregon Public Employees Retirement Fund Purchases 368 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Oregon Public Employees Retirement Fund increased its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDMGet Rating) by 2.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,665 shares of the medical device company’s stock after purchasing an additional 368 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Tandem Diabetes Care were worth $893,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. PNC Financial Services Group Inc. lifted its position in Tandem Diabetes Care by 2.7% during the first quarter. PNC Financial Services Group Inc. now owns 6,246 shares of the medical device company’s stock worth $726,000 after purchasing an additional 164 shares during the period. Securian Asset Management Inc. lifted its position in Tandem Diabetes Care by 3.2% during the second quarter. Securian Asset Management Inc. now owns 5,831 shares of the medical device company’s stock worth $345,000 after purchasing an additional 179 shares during the period. Canada Pension Plan Investment Board lifted its position in Tandem Diabetes Care by 3.4% during the first quarter. Canada Pension Plan Investment Board now owns 5,616 shares of the medical device company’s stock worth $654,000 after purchasing an additional 184 shares during the period. Comerica Bank lifted its position in Tandem Diabetes Care by 0.7% during the second quarter. Comerica Bank now owns 29,239 shares of the medical device company’s stock worth $1,698,000 after purchasing an additional 217 shares during the period. Finally, Cambridge Investment Research Advisors Inc. lifted its position in Tandem Diabetes Care by 5.1% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 6,179 shares of the medical device company’s stock worth $296,000 after purchasing an additional 300 shares during the period. Institutional investors own 96.50% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on TNDM shares. Lake Street Capital cut their price objective on shares of Tandem Diabetes Care from $150.00 to $60.00 in a research report on Thursday, November 3rd. Raymond James lowered their target price on Tandem Diabetes Care from $92.00 to $52.00 and set an “outperform” rating for the company in a research note on Friday, November 4th. Barclays started coverage on Tandem Diabetes Care in a research note on Monday, October 17th. They set an “overweight” rating and a $75.00 target price for the company. Wells Fargo & Company raised Tandem Diabetes Care from an “underweight” rating to an “equal weight” rating and set a $43.00 target price for the company in a research note on Tuesday, November 15th. Finally, Citigroup boosted their target price on Tandem Diabetes Care from $50.00 to $55.00 in a research note on Monday, December 12th. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Tandem Diabetes Care currently has an average rating of “Moderate Buy” and a consensus target price of $75.50.

Insider Buying and Selling at Tandem Diabetes Care

In other Tandem Diabetes Care news, COO David B. Berger sold 10,000 shares of the stock in a transaction that occurred on Friday, December 16th. The shares were sold at an average price of $40.25, for a total transaction of $402,500.00. Following the completion of the sale, the chief operating officer now owns 3,029 shares of the company’s stock, valued at approximately $121,917.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.20% of the company’s stock.

Tandem Diabetes Care Stock Performance

NASDAQ:TNDM opened at $41.59 on Wednesday. The company has a 50 day simple moving average of $41.98 and a two-hundred day simple moving average of $48.67. The company has a debt-to-equity ratio of 0.67, a current ratio of 4.81 and a quick ratio of 4.20. Tandem Diabetes Care, Inc. has a fifty-two week low of $33.51 and a fifty-two week high of $124.90.

Tandem Diabetes Care (NASDAQ:TNDMGet Rating) last released its earnings results on Wednesday, November 2nd. The medical device company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.24). The firm had revenue of $204.55 million for the quarter, compared to analyst estimates of $205.88 million. Tandem Diabetes Care had a negative net margin of 8.59% and a negative return on equity of 8.34%. On average, analysts forecast that Tandem Diabetes Care, Inc. will post -0.77 earnings per share for the current year.

Tandem Diabetes Care Company Profile

(Get Rating)

Tandem Diabetes Care, Inc engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006, and is headquartered in San Diego, CA.

Featured Articles

Want to see what other hedge funds are holding TNDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care, Inc. (NASDAQ:TNDMGet Rating).

Institutional Ownership by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.